KRRO
HealthcareKorro Bio, Inc.
$8.00
$-0.05 (-0.62%)
Jan 5, 2026
Price History (1Y)
Analysis
Korro Bio, Inc. is a biotechnology company in the healthcare sector with 87 employees and a market capitalization of $75.34 million. The company's financial health indicates significant losses, with net income totaling -$88,417,000 over the trailing twelve months (TTM), as well as negative EBITDA (-$89,615,000) and free cash flow ($-41,200,876). Despite having a substantial amount of cash on hand at $92.48 million, Korro Bio has considerable debt of $44.67 million, resulting in a debt-to-equity ratio of 45.10. The company's valuation metrics include a price to book ratio of 0.76 and a price to sales ratio of 10.22, with an EV/EBITDA of -0.31 indicating significant losses relative to market capitalization. The forward P/E ratio is -1.03, and the 52-week high was $55.89, while the low was $5.20.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $75.34M
- P/E Ratio
- N/A
- 52-Week High
- $55.89
- 52-Week Low
- $5.20
- Avg Volume
- 530.81K
- Beta
- 2.53
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 87